Martovitskyi D., Shelest A., Kravchun P.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Relevance: cardiovascular diseases in general and acute myocardial infarction in particular, occupies a leading place among diseases and deaths worldwide, and scientists from all countries pay attention to its study. Consider such a factor of angiogenesis in acute myocardial infarction as endostatin, the effect of which on prediction in acute myocardial infarction is still rather contradictory. Objective: prediction of repeated cardiovascular events during the 6-month observation period in patients after myocardial infarction combined with obesity by the level of angiogenesis index – endostatin. Object and methods: the study involved 105 patients with acute myocardial infarction and concomitant obesity. All patients were divided into 2 groups: 1 group consisted of patients with acute myocardial infarction with concomitant obesity (n = 61), group 2 – patients with acute myocardial infarction without obesity (n = 44). The participants in the study on the first day of acute myocardial infarction were determined to have endostatin levels. Statistical processing was carried out using the program STATISTICA 10.0. (StatSoft Inc, USA). Results: according to the study, it was found that in patients with acute myocardial infarction and obesity, endostatin level was lower than in non-obese patients by 19.14% (p <0.05). It has also been established that endostatin has a high prognostic value regarding the prediction of repeated cardiovascular events in the form of unstable angina and/or acute myocardial infarction during a 6-month follow-up period after a myocardial infarction, so at a level of> 165,41 pmol/L it has as high specificity (95.2%) and sensitivity (87.1%), AUC was 0.96. Conclusions: in patients with acute myocardial infarction in the absence of obesity, hyperactivity of the endostatin angiogenesis marker is observed. Endostatin has a high prognostic value for the development of repeated cardiovascular events in a patient during a 6-month follow-up period after a myocardial infarction on the background of obesity in a wide clinical practice.

endostatin, acute myocardial infarction, obesity, angiogenesis. Р

1. World Health Organization. Health statistics and information systems. Geneva: Global Health Estimates World Health Organization; 2015.
2. John R. Petrie, Tomasz J. Guzik, Rhian M. Touyz. Diabetes, Hypertension, and Cardiovascular Disease: Clinical insights and vascular mechanisms. Canadian journal of cardiology. 2018 May;34(5):574-84. DOI: [10.1016/j.cjca.2017.12.005]
3. Polonetsky OL, Polonetsky LZ. Disfunktsiya endoteliya i ateroscleroz. Meditsinskiye novosti. 2012;6;6-11. [in Russiаn].
4.  Hebert C, Siavash H, Norris K, Nikitakis NG, Sauk JJ. Endostatin inhibits nitric oxide and diminishes VEGF and collagen XVIII in squamous carcinoma cells. Int J Cancer. 2005;114(2):195-201. DOI: 10.1002/ijc.20692
5. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution, and antiangiogenic activity. J Mol Biol. 2000;301:1179-90.
6. Zatterstrom UK, Felbor U, Fukai N, Olsen BR. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct. 2000;25:97-101.
7. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-85.
8. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res. 2002;62:1944-7.
9. Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 2000;14:2373-6.
10.  Sponder M, Dangl D, Kampf S, Fritzer-Szekeres M, Strametz-Juranek J. Exercise increases serum endostatin levels in female and male patients with diabetes and controls. Cardiovasc Diabetol. 2014;13:6.
11.  Sponder M, Sepiol K, Lankisch S, Priglinger M, Kampf S, Litschauer B. Endostatin and physical exercise in young female and male athletes and controls. Int J Sports Med. 2014;35:1138-42. DOI: 10.1055/s-0034-1375692
12. Carlsson AC, Ruge T, Sundström J, Ingelsson E, Larsson A, Lind L. Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage novelty and significance. Hypertension. 2013;62:1146-51. DOI: 10.1161/HYPERTENSIONAHA.113.02250
13.  Ärnlöv J, Ruge T, Ingelsson E, Larsson A, Sundström J, Lind L. Serum endostatin and risk of mortality in the elderly significance. Arterioscler Thromb Vasc Biol. 2013;33(11):2689-95. DOI: 10.1161/ATVBAHA.113.301704
14.  Ruth McPherson. Obesity and Ischemic Heart Disease. Circulation Research. 2015;116(4):570-1.
15. Chenlong Zheng, Panchu Yang, Lu Zhang, Zhiyong Wang, Kun Chen, Yue Lan, et al. Angiogenesis and expression of vascular endothelian growth factor and endostatin protein in myocardial infarction rat model. Bangladesh journal pharmacology. 2016;11:1-7. DOI: http://dx.doi. org/10.3329/bjp.v11i0.26416
16.  Toralph Ruge, Axel C. Carlsson, Jan-Hakan Jansson, Stefan Soderberg, Anders Larsson, Johan Arnlov. The association between circulating endostatin levels and incident myocardial infarction. Scandinavian cardiovascular journal. 2018. DOI: 10.1080/14017431.2018.1547839
17. Wang H, Chen Y, Lu X, Liu G, Fu Y, Luo Y. Endostatin Prevents Dietary-Induced Obesity by Inhibiting Adipogenesis and Angiogenesis. Diabetes. 2015 Jul;64(7):2442-56. DOI: 10.2337/db14-0528

«Bulletin of problems biology and medicine» Issue 2 Part 1 (150), 2019 year, 160-163 pages, index UDK 616.127-005.8-136.11-037-078:57.088.6

10.29254/2077-4214-2019-2-1-150-160-163